Pharmesis International Ltd. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, revenue was RMB 16.014 million against RMB 17.732 million last year. Profit from operations was RMB 0.975 million against loss from operations of RMB 0.905 million last year. Profit before tax was RMB 0.767 million against loss before tax of RMB 0.222 million last year. Profit attributable to equity holders of the company was RMB 0.254 million against loss attributable to equity holders of the company of RMB 0.121 million last year. Net cash flows from operating activities were RMB 8.096 million against RMB 0.497 million last year. Acquisition of property, plant and equipment was RMB 0.21 million against RMB 0.26 million last year. Earnings per share on fully diluted basis were 1.27 cents against loss per share on fully diluted basis of 0.60 cents last year. The group's revenue decreased mainly due to lower sales from its prescribed drugs segment as a result of continued intense competition.

For the nine months, revenue was RMB 46.064 million against RMB 45.718 million last year. Loss from operations was RMB 1.055 million against loss from operations of RMB 3.723 million last year. Profit before tax was RMB 1.511 million against loss before tax of RMB 1.704 million last year. Profit attributable to equity holders of the company was RMB 0.7 million against loss attributable to equity holders of the company of RMB 0.699 million last year. Net cash flows from operating activities were RMB 6.445 million against RMB 4.107 million last year. Acquisition of property, plant and equipment was RMB 1.423 million against RMB 0.294 million last year. Earnings per share on fully diluted basis were 3.50 cents against loss per share on fully diluted basis of 3.50 cents last year.